Table 3.
Effect of the 21-Gene RS Assay on Treatment Recommendations for Patients With N+/ER+ Breast Cancer
| Effect on Recommendation | RS |
|||||||
|---|---|---|---|---|---|---|---|---|
| Low (< 18, n = 72) |
Intermediate (18-30, n = 53) |
High (≥ 31 n = 13) |
All (n = 138)* |
|||||
| No. | % | No. | % | No. | % | No. | % | |
| Any change | 43 | 60 | 20 | 38 | 7 | 54 | 70 | 51 |
| Decreased intensity† | 35 | 49 | 11 | 21 | 0 | 0 | 46 | 33 |
| Increased intensity‡ | 4 | 5 | 6 | 12 | 3 | 23 | 13 | 9 |
| Other§ | 4 | 5 | 3 | 6 | 4 | 31 | 11 | 8 |
| No change | 29 | 40 | 33 | 62 | 6 | 46 | 68 | 49 |
Abbreviations: RS, recurrence score; N+/ER+, node-positive/estrogen receptor–positive.
*
Excludes 22 patients with no treatment recommendations before assay.
†
Decreased intensity = chemotherapy plus hormonal therapy → hormonal therapy alone.
‡
Increased intensity = hormonal therapy alone → chemotherapy plus hormonal therapy.
§
Eleven patients were recommended treatment changes that did not fit our definitions of either increased or decreased intensity (eg, changes in chemotherapy components only or changes from hormonal therapy alone to chemotherapy alone).